

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **1999-06-04** | Period of Report: **1999-06-03**
SEC Accession No. **0000927016-99-002284**

([HTML Version](#) on secdatabase.com)

FILER

NITINOL MEDICAL TECHNOLOGIES INC

CIK: **1017259** | IRS No.: **954090463** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-21001** | Film No.: **99640830**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
27 WORMWOOD STREET
BOSTON MA 02210

Business Address
27 WORMWOOD STREET
BOSTON MA 02210
6177370930

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported)

June 3, 1999

NITINOL MEDICAL TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other
jurisdiction of
incorporation)

0-21001

(Commission File
Number)

95-4090463

(IRS Employer
Identification No.)

27 Wormwood Street
Boston, Massachusetts 02210

(Address of principal executive offices)

Registrant's Telephone Number, including
area code: (617) 737-0930

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On June 3, 1999, the shareholders of Nitinol Medical Technologies, Inc. (the "Company") approved a Certificate of Amendment to the Company's Second Amended and Restated Certificate of Incorporation (the "Certificate of Amendment"), which changed the Company's name to NMT Medical, Inc. The change in the Company's name reflects the Company's transition from a nitinol-based medical device manufacturer to a company supplying a broad range of medical or

health care related products. On June 3, 1999, the Company filed the Certificate of Amendment with the Secretary of State's Office for the State of Delaware.

On June 3, 1999, the Company issued a press release regarding shareholder approval of the Certificate of Amendment. A copy of this press release is attached as an exhibit to this Form 8-K and is incorporated herein by reference.

Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.

(c) Exhibits:

Exhibit Number	Description
-----	-----
99.1	Press Release dated June 3, 1999

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 3, 1999

NITINOL MEDICAL TECHNOLOGIES, INC.

By: /s/ William J. Knight

William J. Knight,
Vice President - Finance and Administration
and Chief Financial Officer

Index to Exhibits

Exhibit Number	Description
-----	-----
99.1	Press Release dated June 3, 1999

[LETTERHEAD OF FRB APPEARS HERE]

The Financial Relations Board Inc.

FOR FURTHER INFORMATION:

AT THE COMPANY

Thomas M. Tully
President & CEO
(617) 737-0930

AT THE FINANCIAL RELATIONS BOARD

General Info: Paula Schwartz
Analyst Info: Brian Gill
Media Info: Deanne Eagle
(212) 661-8030

FOR IMMEDIATE RELEASE

June 3, 1999

NITINOL MEDICAL TECHNOLOGIES ANNOUNCES SHAREHOLDER APPROVAL

OF NAME CHANGE TO NMT MEDICAL, INC,

Shareholders Also Ratify Election of All Seven Members of the Board of Directors

Boston, MA, June 3, 1999 - Nitinol Medical Technologies, Inc., (d/b/a "NMT Medical") (Nasdaq/NMS;NMTI) today announced that at its Annual Meeting held this morning, shareholders approved the official change in the Company's name to NMT Medical, Inc. Shares of NMT Medical will continue to trade on the Nasdaq National Market under the symbol NMTI.

The Company also announced that its shareholders had ratified the election of all seven members of the Board of Directors.

Thomas M. Tully, President and Chief Executive Officer of NMT Medical said that the Company decided to change its name in order to better reflect the diversified range of products it now offers. The Company was founded in 1986 to design, develop and commercialize medical devices specifically engineered using thermal shape-memory nitinol, a nickel-titanium alloy. The Company's first two FDA-approved products, the Simon Nitinol Vena Cava Filter(R) and the Symphony(TM) stent, were both among the first medical devices to be fabricated from thermal shape-memory nitinol.

In recent years, however, NMT Medical has expanded its product portfolio through the acquisition of the CardioSEAL(R) Septal Occluder (a cardiac implant designed to close holes in the heart), NMT Neurosciences (a division of NMT Medical which provides a number of market leading products for the neurosurgery market), and a minority investment in Image Technologies Corporation (a privately held company which is developing products aimed at the endoscopic

market).

Nitmol Medical Technologies Announces
Shareholder Approval of Name Change to NMT Medical, Inc.
Page 2

NMT Medical designs, develops and markets innovative medical devices that utilize advanced technologies and are delivered by minimally invasive procedures. The Company's products are designed to offer alternative approaches to existing complex treatments, thereby reducing patient trauma, shortening procedure, hospitalization and recovery times, and lowering overall treatment costs. The Company's medical devices include self-expanding stents, vena cava filters and septal repair devices. The NMT Neurosciences division serves the needs of neurosurgeons with a range of products including cerebral spinal fluid shunts, the Selector (R) Ultrasonic Aspirator, Ruggles (TM) Surgical Instruments, the Spetzler (TM) Titanium Aneurysm Clip, and endoscopes and instrumentation for minimally invasive surgery.

Image Technologies Corporation is a privately held company, owned 23% by NMT Medical, Inc., which is developing a line of advanced imaging products for minimally invasive surgery which require less equipment, are easier to use, reduce procedure time and personnel requirements, improve operating room efficiency and reduce overall treatment costs.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under the heading "Certain Factors That May Affect Future Results" included in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the year ended December 31, 1998.

To receive NMT Medical's latest news release and other corporate documents via FAX- at no cost - please dial 1-800-PRO-INFO. Enter the Company's symbol NMTI.

###